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The  poor  solubility  of  drugs  remains  one  of the most  challenging  aspects  of  formulation  development.
Aiming  at  improving  the biopharmaceutical  limitations  of  the  calcium  channel  blocker  nimodipine,  the
development  of  solid  dispersions  is proposed  herein.  Three  different  proportions  of nimodipine:HPMC
were tested  and  all  of  them  generated  amorphous  solid  dispersions.  Improvements  of  up 318% in  theeywords:
imodipine
PMC
olid dispersion
solubility  and  a 4-fold  increase  in the  dissolution  rate of  nimodipine  were  achieved.  Stability  studies
conducted  over  90 days  in  a desiccator  indicated  that the initial  characteristic  of the  formulations  were
maintained.  However,  at  40 ◦C/75%  RH  recrystallization  was  observed  for solid  dispersions  with  70  and
80%  of  HPMC,  whilst  the  formulation  composed  of  90%  of the carrier  remained  amorphous.  The  increase  in
the stability  observed  when  the HPMC  concentration  was increased  from  70 to  90%  in the  solid  dispersions
tion  iopharmaceutical properties was  attributed  to the dilu
. Introduction
Together with the permeability, the solubility behavior of an
ctive pharmaceutical ingredient (API) is the limiting step in terms
f its oral bioavailability (Leuner & Dressman, 2000), particularly
or drugs with low gastrointestinal solubility and high permeability
Vasconcelos, Sarmento, & Costa, 2007). Currently, it is estimated
hat 70% of the new APIs have poor aqueous solubility (Ku & Dublin,
010), and unfortunately, around 40% of newly developed drugs
re rejected by the pharmaceutical industry due to their deﬁcient
iopharmaceutical properties (Svenson, 2009).
Several formulation strategies have been proposed to improve
he solubility and dissolution rate of poorly water-soluble APIs
nd of these the solid dispersion (SD) technique has emerged
s a particularly effective approach (Alonzo et al., 2011; Konno,
anda, Alonzo, & Taylor, 2008; Newman, Knipp, & Zograﬁ, 2012;
asconcelos et al., 2007). This technological tool can be deﬁned
s the molecular dispersion of a drug in one or more hydrophilic
arriers (Padden et al., 2011; Vasconcelos et al., 2007) and its mech-
nism involves the reduction of the particle size, the enhancement
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of the wettability of the API in the carrier, the formation of solu-
ble complexes and the obtainment of an amorphous drug (Craig,
2002; Zhong, Zhu, Luo, & Su, 2013). In SDs, hydrophilic polymers
also play an important role inhibiting the crystallization of the API
through decreasing its molecular mobility (Bhugra & Pikal, 2008;
Yonemochi, Sano, Yoshihashi, & Terada, 2013). In this context, the
selection of the ideal carrier is crucial to formulation success (Li
et al., 2013).
Hydroxypropylmethyl cellulose (HPMC), Fig. 1A, is a non-ionic
and water soluble polymer (Rogers, 2009), a mixed cellulose
ether (Leuner & Dressman, 2000), which is of great importance
as a carrier in drug release systems, including SDs  (Asare-Addo,
Levina, Rajabi-Siahboomi, & Nokhodchi, 2011; Colombo, 1993;
Leuner & Dressman, 2000; Pham & Lee, 1994). In this regard,
HPMC is able to enhance the biopharmaceutical properties of many
drugs. Etravirine (Qi et al., 2013), fenoﬁbrate (Kalivoda, Fischbach,
& Kleinebudde, 2012), mesalazine (Ugandhar, 2012), tacrolimus
(Yoshida et al., 2012), raloxifene hydrochloride (Shim et al., 2013)
and resveratrol (Wegiel, Mauer, Edgar, & Taylor, 2013) are some
of the most recent examples. Publications in the literature report
that HPMC can control the drug release rate due to its swelling
and dissolution properties in aqueous solution, which are proba-
bly associated with the formation of soluble complexes between
the water-soluble polymeric carrier and the poorly-water-soluble
drug (Oh et al., 2012).
Nimodipine (NMP), Fig. 1B, is a dihydropyridine calcium channel
blocker recommended for patients with subarachnoid hemorrhage
M.K. Riekes et al. / Carbohydrate Polymers 99 (2014) 474– 482 475
O
O
O
OR
OR
OR
O
OR
OH
RO
OR
H
H
N
NO2
CH3H3C
O
O
CH3
O
OH3C
CH3 O
A B
n – 2
2
er H
(
i
i
2
a
I
h
(
(
o
r
&
&
K
P
P
2
R
T
m
n
t
e
(
p
1
N
s
o
t
s
2
r
s
d
m
s
2
2
p
b
f
tFig. 1. (A) Monomeric unit of HPMC, where R represents eith
Nguyen, 2004). This compound, which presents low bioavailabil-
ty (only 13%) and poor solubility in water, belongs to class II
n the Biopharmaceutical Classiﬁcation System (BCS) (Sweetman,
009), which makes it an ideal candidate for SDs. However, as
n aggravating factor, it presents two polymorphs; Modiﬁcation
 (Mod I) or the metastable form, a racemic compound that exhibits
igher solubility in water (360 ± 70 g L−1), and Modiﬁcation II
Mod II), the stable polymorph, which is chemically a conglomerate
Grunenberg, Keil, & Henck, 1995).
Some attempts to improve the biopharmaceutical properties
f NMP  through SDs obtained via classical techniques have been
eported (Adinarayana, Rajendran, & Rao, 2010; Babu, Prasad,
 Ramana-Murthy, 2002; Docoslis et al., 2007; Gorajana, Rao,
 Nee, 2011; Jijun et al., 2011; Kreidel et al., 2012; Kumar,
umar, Chanderparkash, & Singh, 2010; Lu, Wang, Ding, &
an, 1995; Papageorgiou, Docoslis, Georgarakis, & Bikiaris, 2009;
apageorgiou et al., 2006; Smikalla & Urbanetz, 2007; Urbanetz,
006; Urbanetz & Lippold, 2005; Wu,  Zhou, & Zhang, 1998; Yunzhe,
ui, Wenliang, & Tang, 2008; Zheng, Yang, Tang, & Zheng, 2007).
he promising results obtained through these studies were deter-
inant in the choice of NMP  as a model drug for the obtainment of
ovel SDs, prepared via an innovative technique and with a poten-
ial carrier.
In comparison with other methods used to obtain SDs, high-
nergy milling has received less attention in the literature
Patterson et al., 2007). However, it can be used to produce amor-
hous materials (Boldyrev, Shakhtshneider, Burleva, & Severtsev,
994) or to form regions of drug/excipient miscibility (Friedrich,
ada, & Bodmeier, 2005). During the milling process, sufﬁcient
train is generated in the solid particles through a combination
f impact and attrition, producing structural changes on the crys-
al and the formation of amorphous regions, particularly on the
urface (Balani, Ng, Tan, & Chan, 2010; Feng, Rodolfo, & Carvajal,
008; Mallick et al., 2008). Unlike other techniques, milling is envi-
onmentally friendly, since it does not require the use of organic
olvents. Also, it consists of a relatively simple process which
oes not require sophisticated equipment and which generally cul-
inates in a decrease in the total experimental time and easier
caling up (Barzegar-Jalali et al., 2010; Colombo, Grassi, & Grass,
009; Gaisford, Dennison, Tawﬁk, & Jones, 2010; Zhong et al.,
013).
In this context, the objective of this study was  to verify the
otential of using HPMC to obtain amorphous and physically sta-
le ball-milled SDs containing NMP. The aim of preparing these
ormulations was to improve the biopharmaceutical properties of
he API., CH3 or CH2CH(CH3)OH; (B) chemical structure of NMP.
2. Experimental
2.1. Materials
NMP  was purchased from Chang Zhow ComWin Fine Chemi-
cals (batch 20110305; Jiangsu, China) and HPMC (Methocel K4 M®)
originating from Dow Chemical Company (Midland, USA) was
kindly donated by Colorcon do Brasil LTDA (batch TD 100112N11;
Cotia, Brazil). High-performance liquid chromatography (HPLC)-
grade acetonitrile and methanol were obtained from J.T. Baker
(Phillipsburg, NJ). All other chemicals used were pharmaceutical
grade. During the analysis, ultrapure water was  obtained using a
Milli-Q Gradient System (Millipore, Bedford, MA).
2.2. Methods
2.2.1. Preparation of ball-milled SDs
Firstly, the drug and carrier were accurately weighed to give a
ﬁnal mass of 2.5 g for all of the formulations prepared. SDs com-
posed of 1:9, 2:8 and 3:7 of NMP:HPMC (w/w) were denoted as
1:9 SD, 2:8 SD and 3:7 SD, respectively. Samples were milled in
a Spex Dual Mixer Mill 8000 D (New Jersey, USA) in 40 mL  steel
jars for 180 min, at a ball:powder ratio of 4:1 (w/w)  and with three
steel balls (two with an external diameter of 6.4 mm and one of
12.8 mm).  Milling was  performed at room temperature and no
heating of the samples was  noted at the end of the process.
2.2.2. Preparation of physical mixtures
Physical mixtures were prepared through simple spatulation of
drug and carrier, accurately weighed in different proportions. Sam-
ples were denoted as 1:9 PM,  2:8 PM and 3:7 PM,  corresponding to
NMP:HPMC ratios (w/w)  of 1:9, 2:8 and 3:7, respectively.
2.2.3. Stability studies
The samples were stored in a desiccator under vacuum at 40 ◦C
and with 75% of relative humidity (NaCl saturated solution). Solid
state stability studies on the SDs of NMP  were conducted over a
period of 90 days.
2.2.4. HPLC analysis
The LC analysis was performed through a stability-indicating
LC-method previously described in the literature (Riekes et al.,
2013) and employing a Shimadzu LC-10A system (Kyoto, Japan)
equipped with an LC-10AD pump, DGU-14A degasser, SPD-10AV
variable-wavelength detector (set at 235 nm)  and an SCL-10AVP
system controller unit. The experiments were conducted on a
4 rate P
r
u
4
p
(
s
t
w
w
e
o
2
S
c
t
i
D
d
r
b
B
2
2
w
P
r
v
d
s
s
a
c
o
d
r
s
2
a
(
w
c
a
(
a
w
a
i
r
u
p
o
2
w
a
o
m
p76 M.K. Riekes et al. / Carbohyd
eversed-phase Phenomenex (Torrance, CA) Luna C18 col-
mn  (250 × 4.6 mm i.d., 5 mm).  A security guard holder (C18,
.0 × 3.0 mm i.d.) was employed to protect the column. The mobile
hase was isocratically composed of acetonitrile:methanol:water
55:11:34 v/v/v), with a ﬂow rate of 0.5 mL  min−1, at 40.0 ◦C. The
amples (at a theoretical concentration of 20 g mL−1) were ﬁl-
ered through a 0.45 mm membrane ﬁlter and a volume of 20 L
as injected. Data acquisition was performed using CLASS-VP soft-
are to measure the detected peaks. The content of NMP  in SDs was
xpressed as relative values in relation to the theoretical content
f the drug in formulations.
.2.5. Measurement of solubility
In order to determine the NMP  solubility, an excess of drug in
Ds was weighed and added to 30 mL  of acetate buffer (pH 4.5)
ontaining 0.3% of sodium lauryl sulfate (SLS), giving a ﬁnal concen-
ration of 2.0 mg  mL−1. Samples were kept under stirring at 150 rpm
n a thermostatically controlled water bath (37 ± 2 ◦C) (Dist, model
I-06) until a constant concentration of NMP  was reached. At pre-
etermined intervals, aliquots were withdrawn (with immediate
eplacement of fresh solution) and ﬁltered through 0.22 m ﬁlters
efore taking the readings on a UV/VIS spectrophotometer (Cary 50
IO, Varian) at 340 nm.
.2.6. Solid-state characterization of ball-milled SDs
.2.6.1. X-ray powder diffraction (XRPD). X-ray diffraction patterns
ere obtained using a - X-ray diffractometer (Xpert Pro Multi-
urpose Diffractometer, PANAlytical) equipped with K copper
adiation ( = 1.5418 A˚), operating with a 40 mA  current and 45 kV
oltage, sample spinner and a Real Time Multiple Strip (RTMS)
etector. The measurements were performed at room temperature,
canning at 2 from 5◦ to 50◦, with a 0.03342◦ step size and 10.16 s
tep time.
During the stability studies, the diffractograms were acquired on
 – X-ray diffractometer (D2 Phaser, Bruker), operating with K
opper radiation ( = 1.5418 A˚), at a current of 10 mA and voltage
f 30 kV. Detection was performed on a scintillation counter one-
imensional LYNXEYE detector. The measurements were taken at
oom temperature, scanning at 2 from 5◦ to 50◦, with a 0.091◦ step
ize.
.2.6.2. Thermal analysis. Differential scanning calorimetry (DSC)
nalysis was carried out in triplicate using a Shimadzu calorimeter
DSC-60), operating in a temperature range of 40–130 ◦C. Samples
eighing approximately 2 mg  were heated in sealed aluminum
rucibles (model 201-53090) and scanned at a ﬁrst scan mode,
t a heating rate of 2 ◦C min−1 and under nitrogen air atmosphere
50 mL  min−1). The DSC cell was previously calibrated with indium
nd zinc.
The mass loss of the samples as a function of temperature
as determined in triplicate using a Shimadzu thermobal-
nce (TGA-50). Approximately 3 mg  of samples were placed
n open platinum crucibles which were heated at a heating
ate of 20 ◦C min−1, to temperatures ranging from 40 to 800 ◦C
nder nitrogen atmosphere (50 mL  min−1). The instrument was
reliminarily calibrated with a standard reference of calcium
xalate.
The thermal data obtained were processed using TA60 software.
.2.6.3. Fourier transform infrared (FTIR) spectroscopy. FTIR spectra
ere acquired on a Shimadzu spectrophotometer (FTIR Prestige),
t room temperature, from 4000 to 400 cm−1, with the collection
f 20 scans at a resolution of 4 cm−1. Samples were prepared by
ixing 2% (w/w) of the drug, carrier, physical mixtures and SDs in
otassium bromide (KBr).olymers 99 (2014) 474– 482
2.2.6.4. Scanning electron microscopy (SEM). The samples were
mounted on aluminum stubs, sputtered with gold (IC-50 Ion Coater,
Shimadzu, Kyoto, Japan) and analyzed using a scanning electron
microscope (SSX-550 Superscan, Shimadzu, Kyoto, Japan) at an
accelerating voltage of 10 or 15 kV with different magniﬁcations.
2.2.7. In vitro dissolution studies
Dissolution studies of the NMP  and SDs were performed using
the Varian VK 7000 dissolution device and dissolution apparatus
II (paddle), according to the speciﬁcations of British Pharmacopeia
(British Pharmacopoeia, 2009), which describes the in vitro evalu-
ation of NMP  tablets. A known amount of the drug (30 mg)  was
weighed and submitted to dissolution in 900 mL of previously
deaerated acetate buffer (pH 4.5) containing 0.3% of SLS, kept at
37 ± 0.5 ◦C and rotated at 75 rpm. At predetermined time intervals
(5, 10, 15, 20, 25, 30, 45 and 60 min) 4 mL  aliquots were withdrawn
(with immediate replacement of fresh dissolution medium) and
ﬁltered through 0.22 m ﬁlters before readings were taken on a
UV/VIS spectrophotometer (Varian UV/VIS CARY) at 340 nm. The
correction for the cumulative dilution was calculated. Dissolution
experiments were carried out in triplicate and in the absence of
light.
Dissolution proﬁles for the NMP  and SDs were compared by
independent and dependent methods. For the model-independent
analysis, the dissolution efﬁciency (DE) of the drug and SDs was
established. In this analysis the area under the dissolution curve at
time t was  calculated through the trapezoidal rule and expressed
as the percentage of the rectangle area described by 100% of dis-
solution within the same period. The area under the curve was
determined using the Image Tool software, version 3.0. In vitro
proﬁles were also investigated by model-dependent methods,
and the data were tested to ﬁt ﬁrst-order, zero-order, Hixson-
Crowell and Higuchi models (O’Hara, Dunne, Butler, & Denave,
1998; Polli, Rekhi, & Shah, 1996). The selection of the model-
dependent method was based on the best ﬁt obtained, determined
by considering the correlation coefﬁcient (r) most similar to 1. The
semi-empirical Korsmeyer–Peppas model was also evaluated cor-
relating drug release to time through a simple exponential equation
(Mt/M∞ = k.tn). In this context, Mt/M∞ corresponds to the propor-
tion of drug released at time t, k is the kinetic constant, and it
has been proposed that the exponent n is indicative of the release
mechanism (Korsmeyer, Gurny, Doelker, Buri, & Peppas, 1983).
3. Results and discussion
3.1. HPLC analysis
The experimental and relative values regarding the contents of
NMP  in SDs were 100.61 ± 0.43%, 98.98 ± 0.04% and 99.43 ± 0.35%
for 1:9 SD, 2:8 SD and 3:7 SD, respectively. Also, no degradation
peak was  observed in the chromatograms analyzed (Supplemen-
tary Fig. A.1), indicating the stability of the drug on employing this
technique.
Supplementary material related to this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.carbpol.2013.08.046.
3.2. Measurement of solubility
The results obtained for the NMP  solubility indicated that
improvements were achieved for all of the SDs. Increases of
318.80 ± 1.31%, 156.14 ± 1.29% and 102.87 ± 0.99% were observed
for 1:9 SD, 2:8 SD and 3:7 SD, respectively. These data indicate that
the solubility of NMP  in these SDs was dependent on the carrier
concentration, the best result being obtained for the formulation in
which the proportion of HPMC was 90% with 10% of NMP. Also, the
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Fig. 2. Calculated X-ray patterns of Mod  I and Mod  II and X-ray diffractograms of
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t  6.6◦ , characteristic of Mod  I, whilst  indicates the reﬂection at 9.3◦ , which is
resent exclusively at Mod  II.
ncreased solubility of NMP  in the presence of HPMC could be due
o the formation of soluble complexes between the water-soluble
olymeric carrier and poorly soluble drug (Oh et al., 2012).
.3. Solid-state characterization of ball-milled SDs
.3.1. XRPD
X-ray diffraction patterns related to the NMP  crystalline phases
Mod I and Mod  II) and the raw material, HPMC, physical mixtures
nd SDs are shown in Fig. 2.
According to Grunenberg, Keil and Henck, NMP  presents two
rystalline phases: Modiﬁcation I (Mod I) or the metastable form,
 racemic compound that exhibits a higher solubility in water
360 ± 70 g L−1), and Modiﬁcation II (Mod II), the stable poly-
orph, chemically deﬁned as a conglomerate (Grunenberg et al.,
995). These crystalline modiﬁcations can be easily distinguished
hrough various solid-state techniques, and the XRPD analysis pro-
uced very different diffractograms for these samples, especially
t low 2 angles. The reﬂection at 6.6◦ is only observed for Mod
, whilst that at 9.3◦ is present exclusively for Mod II (Docoslis
t al., 2007; Guo et al., 2011; Riekes et al., 2012; Yang, Ke, Zi, Liu,
 Yu, 2008). Through these analyses it is possible to afﬁrm that the
aw material acquired for the development of the SDs is composed
xclusively of the metastable polymorph Mod  I.
On the other hand, the carrier is completely amorphous, in
greement with previous data reported in literature (Cilurzo,
inghetti, Casiraghi, & Montanari, 2002; Oh et al., 2012). For all of
he physical mixtures, it is possible to observe the crystalline reﬂec-
ions of the drug overlapping the amorphous halo of the polymer.
hese data indicate the absence of physical interactions betweenFig. 3. (A) DSC curves and (B) TGA curves of raw materials and SDs. In the upper
right corner of (B), derivate thermogravimetric curves (DrTGA) of the samples are
presented.
NMP  and HPMC and also verify that amorphous halos related to the
SDs are due to the preparation process.
In order to determine the drug behavior during milling without
a polymeric carrier, NMP  was milled for 3 h. It is extremely impor-
tant to note that without HPMC the API did not become amorphous.
In addition, the initial polymorph Mod  I underwent a partial solid-
state transition to the less soluble crystalline phase Mod  II, since
both characteristic reﬂections at 6.6◦ (Mod I) and at 9.3◦ (Mod II)
were observed for this sample. These data demonstrate the impor-
tance of adding HPMC to obtain amorphous SDs  containing NMP.
Also, as can be observed, all of the SDs showed amorphous char-
acteristics, explaining the increase in the solubility of NMP  in these
formulations. The enhanced solubility is the result of the disor-
dered structure of the amorphous solid. Because of the short-range
intermolecular interactions in an amorphous system no lattice
energy has to be overcome, whereas in the crystalline material
the lattice has to be disrupted in order for it to dissolve (Sathigari,
Radhakrishnan, Davis, Parsons, & Babu, 2012; Shah, Kakumanu, &
Bansal, 2006).
3.3.2. Thermal analysis
The DSC and thermogravimetric curves for the drug, carrier and
SDs are shown in Fig. 3. According to Grunenberg, Keil and Henck
NMP  polymorphs can be also distinguished by means of DSC, since
Mod I shows an endothermic event at 124 ± 1 ◦C and Mod  II melts
at 116 ± 1 ◦C (Grunenberg et al., 1995). As can be observed, the NMP
raw material presented a single melting event at 124.1 ◦C, conﬁrm-
ing its identity as pure Mod  I. These data are in agreement with
the previous XRPD results. No endothermic event was observed
for HPMC, which is consistent with data reported in the literature
(Asare-Addo et al., 2011). However, discrete endothermic events
at 115 and 125 ◦C were observed for the sample 3:7 SD,  indicating
a crystallization of NMP  into its two polymorphs during the DSC
478 M.K. Riekes et al. / Carbohydrate Polymers 99 (2014) 474– 482
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Fig. 4. FTIR spectra of raw m
nalysis, at elevated temperatures. The absence of crystallization
r melting events for the samples 1:9 SD and 2:8 SD, besides indi-
ating their amorphous state, may  be due to the lower contents
f drug in these samples, which are probably lower than the lim-
ts of detection for each polymorph (Riekes et al., 2012). It is very
mportant to mention that the endothermic events found for the
ample 3:7 SD does not indicate that this SD is crystalline, since the
-ray analysis veriﬁed its amorphous state. In addition, although a
ingle glass transition temperature (Tg) was expected to verify the
iscibility of the amorphous phases in the obtained SDs (Palermo,
nderson, & Drennen, 2012), none of the DSC curves showed it. This
act can be explained by the very broad Tg of the heterogeneous
PMC.
The thermogravimetric analysis revealed that the NMP  was
hermally stable up to approximately 250 ◦C, presenting a single
eight loss event (96.2%) in the temperature range analyzed. The
hermal degradation peak, obtained through derivative thermo-
ravimetry, occurred at 347.2 ◦C. These data are in agreement with
revious reports in the literature (Cardoso, Rodrigues, Stulzer, Silva,
 Matos, 2005). A higher thermal stability was noted for HPMC, also
n a single stage of degradation. The thermal degradation occurs at
etween 335 ◦C and 425 ◦C, with a peak temperature of 391 ◦C. The
eight loss for HPMC was of 93.4%. For the SDs the thermal degra-
ation occurred in two steps (as evidenced by the DrTGA curves),
nd the relative proportion of the two degradation events is directly
roportional to the NMP  and HPMC contents of the samples. The
rst event represents the presence of NMP, whilst the second one
s related to HPMC. The weight losses were 94.2%, 93.7% and 92.3%,
or 1:9 SD, 2:8 SD and 3:7 SD, respectively.
.3.3. FTIR spectroscopy
The FTIR spectra for NMP, HPMC, 1:9 PM and SDs are shown in
ig. 4.
Characteristic bands for NMP  appear at 3293 cm−1, related to
 H stretching of the polymorph Mod  I, at 1695 cm−1, associ-
ted with the carbonyl bond, and at 1523 cm−1, representing the
O2 group (Barmpalexis, Kachrimanis, & Georgarakis, 2011; Huber (cm )
ls, physical mixture and SDs.
et al., 2003; Papadimitriou, Papageorgiou, Kanaze, Georgarakis, &
Bikiaris, 2009; Tang, Pikal, & Taylor, 2002). In the case of HPMC,
bands were observed at 3443 cm−1 (O-H stretching), at 2935 cm−1
(C H stretching), at 1651 cm−1 (C O of the glucose unit) and
at 1069 cm−1 (C O C group) (Anuar, Wui, Ghodgaonkar, & Taib,
2007; Oliveira, Bernardi, Murakami, Mendes, & Silva, 2009). In the
physical mixture, all of the characteristic bands for the drug and
carrier are overlapped, indicating the absence of physical interac-
tions between these compounds. On the other hand, bands related
to the amine group of NMP  disappeared for all of SDs, conﬁrming
the amorphous characteristic of these formulations (Barmpalexis
et al., 2011), as previously observed through XRPD and DSC anal-
ysis. Also, although shifts for the bands related to HPMC were not
observed, the merging of the O H band of the carrier with the N H
band of NMP  indicates the establishment of hydrogen bonding in
SDs. It is important to mention that this kind of interaction between
drug and carrier is an additional beneﬁt for the SDs, since they can
increase the solid solubility of the drug into the hydrophilic carrier
besides acting on inhibiting the crystallization of the drug from a
glass solution (Marsac, Shamblin, & Taylor, 2006; Van den Mooter,
2012). Cilurzo, Minghetti, Casiraghi and Montanari also observed
the disappearance of N H stretching vibrations for amorphous SDs
composed of nifedipine and HPMC (Cilurzo et al., 2002).
3.3.4. SEM
Photomicrographs of the drug, carrier and SDs are shown in Sup-
plementary Fig. A.2. Small tabular crystals with a homogeneous
particle size distribution can be observed for the NMP  raw material.
However, particles with undeﬁned shapes are observed for HPMC.
From these images it can be veriﬁed that the milling promoted
considerable changes in the morphology of the NMP  and HPMC,
generating agglomerates which did not seem to be inﬂuenced by
the drug:carrier proportion. It is important to mention that crystals
of the drug were not observed on the surface of the formulations,
conﬁrming its amorphous characteristic in SDs. Also, as no decrease
in particle size was noted for 1:9 SD, 2:8 SD and 3:7 SD, it is assumed
that the enhancement in NMP  solubility is due to the amorphous
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Table 1
Dissolution efﬁciency (DE), period in which 50% release of NMP  occurs (t50%) and
dissolution rate constant (k) for SDs.
Sample DE (%) ± standard deviation t50% (min) k (min−1)
1:9 SD 71.5 ± 0.9 242.73 16.00
2.3, for 1:9 SD, 2:8 SD and 3:7 SD, respectively, indicating that the
NMP was  released via Super Case II transport. In the case of this
mechanism, it is proposed that the drug release involves diffusion,ig. 5. Release rates of () 1;9 SD, () 2:8 SD, () 3:7 SD and () pure NMP  in acetate
uffer pH 4.5 containing 0.3% of SLS.
haracteristic, the establishment of hydrogen bonding and the pres-
nce of a hydrophilic carrier in SDs, which probably improved the
ettability of these formulations.
Supplementary material related to this article can be
ound, in the online version, at http://dx.doi.org/10.1016/
.carbpol.2013.08.046.
.4. In vitro dissolution studies
The release rates of the different SDs of NMP in acetate buffer
pH 4.5) containing 0.3% of SLS and of the pure drug are compared
n Fig. 5.
As can be observed, all of the SDs were able to increase the
issolution rate of NMP. These data are in agreement with the
nhancement of the drug solubility in these formulations. The for-
ulation 1:9 SD promoted the release of approximately 100% of
MP  in 60 min, which indicates a 3-fold increase in the drug dis-
olution during this period. Also, 2:8 SD and 3:7 SD presented very
imilar release proﬁles for up to 30 min, after which 2:8 SD demon-
trated a higher dissolution rate. According to Kogermann et al.
2013), this deviation in the dissolution behaviors in the later stages
f a dissolution testing could be associated with the formation of
hysically different diffusion layers around the drug:polymer par-
icles, since it is well known that the dissolution of the drug follows
he dissolution of the polymer. The values for the percentage drug
elease of these SDs were 91.2 ± 5.9% (2:8 SD) and 78.8 ± 1.4% (3:7
D) at the end of the assay. These results indicate that the improve-
ent of this biopharmaceutical property was dependent on the
rug:carrier ratio, the best results being obtained for the SD with
he highest proportion of HPMC.
It is also important to mention that the dissolution data for 1:9
D, 2:8 SD and 3:7 SD were within the acceptance criteria of devia-
ion required by the United States Pharmacopoeia. This means that
he relative standard deviation (RSD) values at time intervals of
0 min  or less were lower than 20%, and for longer intervals they
ere lower than 10%. The fulﬁllment of this condition is essential,
ince a high variability in the results can hinder the identiﬁcation
f trends or effects resulting from changes in the formulation (USP,
011). Also, achieving the desired deviation range is even more
hallenging for HPMC-based formulations, since HPMC is known
o form hydrogels which slowly erode in aqueous solutions and
an result in variability among samples (Kim et al., 2006).Data related to the analysis of the dissolution proﬁles through
ndependent and dependent methods are shown in Table 1.
Regarding the dissolution efﬁciency (DE), SDs increased this
alue considerably, since for the pure drug the DE was 19.4 ± 0.6%.2:8 SD 59.0 ± 3.6 246.23 12.88
3:7 SD 58.8 ± 3.7 318.88 12.09
Increases in this parameter by up to a factor of four were noted
for the formulations obtained in comparison to NMP. The release
proﬁles were also tested through different mathematical models
and the best ﬁt was  observed for the Higuchi model. According to
this model, when exposed to the solvent, both the drug and carrier
dissolve at rates proportional to their solubility and diffusion coef-
ﬁcients in the dissolving medium. In this context, the dissolution
rate of the minor component may  be determined by the component
in excess. In turn, this may  be applied to solid dispersal systems by
arguing that when the drug is present as a minority component its
dissolution will be dominated by the dissolution behavior of the
carrier (Corrigan, 1986; Craig, 2002; Higuchi, 1967; Higuchi, Mir,
& Desai, 1965).The Korsmeyer–Peppas model correlates the drug
release to time through a simple exponential equation for a drug
release fraction of <0.6. This model has been used to evaluate the
drug release from polymeric devices, especially when the release
mechanism is unknown or when there is more than one mechanism
involved (Korsmeyer et al., 1983). In this context, n ≤ 0.43 indicates
Fickian release and n = 0.85 indicates a purely relaxation-controlled
delivery which is referred to as Case II transport. Intermediate val-
ues (0.43 < n < 0.85) indicate an anomalous behavior, described as a
non-Fickian kinetics corresponding to coupled diffusion and poly-
mer  relaxation. Occasionally, values of n > 1 have been observed
which are regarded as Super Case II kinetics (Ritger & Peppas,
1987, 1987a).The results obtained through the application of the
Korsmeyer–Peppas model show calculated n values of 2.92, 2.2 andFig. 6. (A) XRPD patterns and (B) DSC curves of SDs after 90 days of stability studies at
different conditions. The arrow at the X-ray pattern of 3:7 SD indicates the reﬂection
at 9.3◦ , characteristic of Mod  II.
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Fig. 7. FTIR spectra of SDs kept 90 days at different conditions. The highlighted
welling, relaxation and erosion (Ritger & Peppas, 1987a) of the
olymeric component.
.5. Stability studies
Stability studies on the physical state of the SDs were performed
hrough XRPD, DSC and FTIR spectroscopy. The data obtained are
hown in Figs. 6 and 7.
As can be observed through XRPD data, all of the SDs remained
morphous for 90 days in a desiccator. No changes were observed
n the FTIR spectra, indicating the maintenance of the initial inter-
ctions between the drug and carrier. These data suggest that the
ormulations remained stable under this condition. Also, the crys-
allization of the sample 3:7 SD during the DSC analysis was  still
bserved and its cause was already discussed in Section 3.3.2.
On the other hand, distinct results were obtained when the sam-
les were submitted to more severe conditions of temperature and
umidity. At 40 ◦C/75% RH, only the sample 1:9 SD remained amor-
hous, as indicated by the XRPD, DSC and FTIR spectroscopy data.
he X-ray diffractograms for 2:8 SD and 3:7 SD clearly indicated the
ecrystallization of these samples, and the characteristic reﬂection
f Mod  II, at 9.3◦, was observed for the formulation 3:7 SD. These
ata were conﬁrmed by the DSC results and the thermal analysis
lso revealed the polymorphic mixture of 2:8 SD. The spectroscopy
nalysis shows the appearance of amine group bands related to
rystalline NMP  at 3269 cm−1 for the samples 2:8 SD and 3:7 SD,
ndicating the presence of the crystalline phase Mod II (Barmpalexis
t al., 2011; Tang et al., 2002).
Reports in the literature indicate that exposure to high humid-
ty leads to a greater absorption of moisture by the bulk structure
f SDs, in addition to surface adsorption, compared to physical
ixtures of similar composition. This absorbed water content can
nduce plasticization and enhance molecular mobility, thereby
eading to crystallization (Ahlneck & Zograﬁ, 1990; Sakurai, Sako, Maitani, 2012; Takeuchi, Yasuji, Yamamoto, & Kawashima,
000).
It is well known that thermodynamically unstable systems, like
morphous systems, tend to undergo recystallization to their moreber (cm-1)
 show the appearance of the amine group bands respective to crystalline NMP.
stable state at any given moment (Serajuddin, 1999). However, var-
ious studies have demonstrated that the presence of hydrophilic
carriers inhibits the recrystallization of amorphous drugs (Bhugra
& Pikal, 2008; Bikiaris, 2011; Leuner & Dressman, 2000; Newman
et al., 2012; Sethia & Squillante, 2003; Van den Mooter, 2012). This
inhibition is generally attributed to the interaction between drug
and carrier, promoted mainly through hydrogen bonds, and to the
dispersion of drug molecules in the polymeric matrix during the
preparation process (Leuner & Dressman, 2000). In the case of SDs
of NMP, the increase in the stability observed when the HPMC con-
centration was increased from 70 to 90% (w/w) was attributed
to the dilution mechanism, where the drug was  diluted in the
polymer and the diffusion pathway for crystallization increased,
thereby slowing the process (Bhugra & Pikal, 2008; Konno & Taylor,
2006).
4. Conclusions
SDs composed of NMP  and HPMC, in different proportions,
were successfully obtained through ball milling and achieved the
desired aims. All of the solid-state techniques demonstrated that
1:9 SD, 2:8 SD and 3:7 SD were amorphous and FTIR data veriﬁed
the establishment of hydrogen bonding between drug and carrier.
The enhancement of the biopharmaceutical properties of the API
was achieved for all formulations, although the best results were
attributed to the sample 1:9 SD. This SD was able to improve the
drug solubility by up 318% and the NMP  dissolution rate by up
to a factor four. In addition to promoting the best performance
in terms of these properties, a higher proportion of HPMC in the
formulations led to a greater stability of the SDs at 40 ◦C/75% RH,
due to a dilution mechanism. No changes were noted for the SDs
over 90 days of storage in a desiccator, with respect to the phys-
ical characteristics. These results verify the potential of HPMC as
a polymeric carrier for ball-milled SDs of NMP  and highlight the
future perspectives for these systems, especially for the sample 1:9
SD, which include the obtainment of solid dosage forms and the
determination of their bioavailability compared with commercial
formulations.
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